GlobeNewswire Inc.··Not SpecifiedCorbus Pharma Eyes Major Catalysts: FDA Alignment on CRB-701, Obesity Drug Data Ahead
Corbus Pharmaceuticals secured FDA alignment on CRB-701 registration pathway, completed obesity drug enrollment, and reported $138.2M cash runway through 2028.
CRBPclinical-stageantibody-drug conjugate